Search clinical trials for: Refametinib (BAY86-9766)

Total 490 results

Bayer

Completed

To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects

Renal Insufficiency, Chronic

Germany
Bayer

Terminated

Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Lymphoma, Mantle-Cell

United States
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
Bayer

Completed

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO)

Advanced or Metastatic Solid Tumor

United States, Spain, Korea, Republic of, Belgium, Singapore, Germany
Bayer

Completed

Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne

Acne Vulgaris

United States
Bayer

Completed

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

Acne Vulgaris

United States
Genzyme, a Sanofi Company

Terminated

Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim

Crohn Disease

United States
Genzyme, a Sanofi Company

Terminated

Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease

Crohn Disease

United States
Genzyme, a Sanofi Company

Completed

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell

Japan
Bayer

Completed

Efficacy and Safety Oral Contraceptive Study

Contraception
Bayer

Completed

Comparative Cycle Control Europe

Contraception

Germany, Czech Republic, France
Bayer

Completed

Maintenance Treatment of Renal Anemia in Dialysis Subjects (MIYABI HD-M)

Renal Insufficiency, Chronic | Anemia

Japan
University of Chicago
Verastem, Inc.

Recruiting

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal Adenocarcinoma

United States
Bayer

Completed

Pilot Study to Assess Number of Patients for Main Trial

Wound Healing

Germany
Bayer

Completed

A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema (DRAKO)

Macular Edema

United Kingdom
Bayer

Completed

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Non-Hodgkin's Lymphoma | Lymphoma, Low-Grade

Japan
Genzyme, a Sanofi Company

Terminated

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Crohn Disease

Israel, United States, Romania, Ukraine, South Africa, Canada, Australia, Bulgaria, Russian Federation, New Zealand, Brazil
Genzyme, a Sanofi Company

Completed

Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease

Crohn Disease
Genzyme, a Sanofi Company

Terminated

Study of Sargramostim in Moderately to Severely Active Crohn's Disease

Crohn's Disease
Bayer

Completed

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse, Large B-Cell, Lymphoma

Belgium, France, Canada, Korea, Republic of, Australia, Germany, United Kingdom, Italy, Denmark, Singapore
Bayer
University of California, San Francisco; Laboratorium für Klinische Forschung; Diagnostic Cytology Laboratory

Completed

Endometrial Safety Study

Postmenopause

Mexico, United States, Italy, Denmark, Austria, Argentina, Brazil, Russian Federation
Bayer

Completed

Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens

Ovulation Inhibition

Germany, Netherlands
Bayer

Completed

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Hong Kong, Turkey, Russian Federation, Singapore, United States, Canada, Germany, Australia, New Zealand, Finland, Austria, United Kingdom, Bulgaria, Hungary, Italy, Israel, Korea, Republic of, Poland, Port... and more
Genzyme, a Sanofi Company

Completed

Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease

Crohn Disease

Switzerland, New Zealand, Canada, Australia, Brazil, Argentina, United Kingdom, Ukraine, Russian Federation
Bayer

Completed

A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components (INDessa)

Contraception

Germany, United Kingdom
Verastem, Inc.
Mirati Therapeutics Inc.

Recruiting

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (RAMP204)

Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | Malignant Neoplasm of Lung | Malignant Neoplastic Disease | KRAS Activating Mutation

United States
Bayer

Completed

Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

Vasomotor Symptoms | Hot Flashes

United States
Bayer

Terminated

Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers

Diagnostic Imaging

Switzerland, Germany
Bayer

Completed

A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects (MIYABI ND-M)

Renal Insufficiency, Chronic | Anemia

Japan
VA Eastern Colorado Health Care System
University of Colorado, Denver; University of Colorado, Boulder

Recruiting

Probiotic (LGG) for Veterans With PTSD

Inflammation | Post Traumatic Stress Disorder

United States
Bayer

Completed

A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects (MIYABI HD-C)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Completed

A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects (MIYABI PD)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Completed

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

Wet Age-related Macular Degeneration

India
Bayer

Completed

Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers

Multiple Sclerosis | Positron-Emission Tomography

Australia, Sweden
Bayer

Recruiting

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

Retinopathy of Prematurity | Newborns | Infants

Japan
Bayer

Completed

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease (XTEND)

Wet Age-related Macular Degeneration

Canada, Spain, Sweden, Belgium, Argentina, Italy, Korea, Republic of, United Kingdom, China, Denmark, France, Norway, Colombia, Australia, Ireland, Switzerland, Thailand
Bayer
Regeneron Pharmaceuticals

Completed

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease (AURIGA)

Macular Edema

Germany, Italy, Russian Federation, Taiwan, China, Egypt, France, Kuwait, Lebanon, Saudi Arabia, United Arab Emirates
Bayer

Completed

Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO (CENTERA)

Central Retinal Vein Occlusion

France, Canada, Denmark, Germany, Italy, Spain, United Kingdom, Australia
Bayer
Regeneron Pharmaceuticals

Completed

Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion (RETRO CRVO)

Retinal Vein Occlusion

Belgium
Bayer

Completed

Angeliq Regulatory Post Marketing Surveillance (Angeliq rPMS)

Osteoporosis, Postmenopausal | Postmenopausal Period

Korea, Republic of
Bayer

Recruiting

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Neovascular Glaucoma

Japan
Bayer
Regeneron Pharmaceuticals

Terminated

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment (XPAND)

Neovascular (Wet) Age-related Macular Degeneration

Canada, United Kingdom
Bayer

Completed

Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer

Breast Neoplasm

United States, Canada
Bayer

Completed

Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido

Libido

Germany
Centre Hospitalier Intercommunal Creteil
Bayer

Completed

Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration (ARI2)

Eye Diseases | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Wet Macular Degeneration

France
Bayer

Completed

Yasmin Post Marketing Surveillance

Contraception

Korea, Republic of
Guerbet
Bayer AG (Sponsor); Bracco (Sponsor); GEHC (Sponsor)

Recruiting

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (ODYSSEY)

Cognitive Function | Motor Function | Contrast Media

United States, Korea, Republic of, Italy, Brazil, Canada, Russian Federation
Bayer

Active, not recruiting

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Hemophilia A

Japan
Bayer

Completed

BAY81-8973 Pediatric Safety and Efficacy Trial

Haemophilia A

Spain, Russian Federation, United States, Hungary, Italy, Mexico, Norway, Romania, Bulgaria, Canada, Argentina, Denmark, Israel, Poland, Ireland, Latvia, Lithuania
Bayer

Withdrawn

Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis (Phoenix)

Dermatitis, Atopic

Germany

3

Subscribe